Medtronic, Inc. et al v. AGA Medical Corporation

Medtronics, Inc. sued AGA Medical Corporation on a patent infringement theory claiming that Defendant's Amplatzer Occluder and vascular plug product lines infringed patents issued to it.



The claims made and defenses asserted are not available.

Plaintiff's verdict for $57 million.

AGA Medical Holdings, Inc. (AGA Medical) today announced the completion of the first phase of a litigation between AGA Medical and Medtronic, Inc., in which a California jury returned a verdict that some of AGA Medical's products infringed some of the claims of patents held by Medtronic, and that these patents have not been proven invalid over prior art. A second, non-jury phase of the trial dealing with other issues of invalidity and unenforceability of the Medtronic patents, which could affect the final outcome, has been scheduled for later this year. The damages awarded in the jury's verdict were about half of what Medtronic had originally sought. In addition, an unrelated case that is currently pending at the U.S. Court of Appeals for the Federal Circuit involves issues that may significantly reduce AGA Medical's liability and any potential damages awarded in this case.
“While we are disappointed with this interim result, AGA Medical will continue to vigorously defend the case,” said John Barr, president and chief executive officer of AGA Medical.

About AGA Medical Holdings, Inc.
AGA Medical Holdings, Inc., based in Plymouth, Minn., is a leader in developing interventional devices for the minimally invasive treatment of structural heart defects and peripheral vascular disorders. Founded in 1995 by Dr. Kurt Amplatz, a former professor and researcher at the University of Minnesota Department of Radiology, AGA Medical develops and commercializes a range of AMPLATZER® products for structural heart repair and circulatory conditions. Several of these devices have been major innovations in the treatment of the most common congenital "holes in the heart," such as atrial septal defects, patent foramen ovale and ventricular septal defects.

More than 700 articles have been published in medical literature that support the benefits of AMPLATZER products, including improved patient outcomes, reduced length of stay and accelerated recovery times. AMPLATZER products have received regulatory approval and are marketed in 101 countries. For more information, visit www.amplatzer.com.

###

Contact:
Kristen Spargo
Padilla Speer Beardsley
612.455.1741
KSpargo@psbpr.com